Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double
Publishing timestamp: 2024-05-02 12:27:22
Summary
Novo Nordisk reported a 28% increase in net profit in the first quarter, driven by strong sales of its weight loss drug Wegovy. The company raised its outlook for 2024 and is facing competition in the weight loss treatment market. Analysts expect continued growth and emphasize the importance of research and development to stay ahead of competitors.
Sentiment: POSITIVE
Keywords: pharmaceuticals, novo nordisk a/s, markets, business news, breaking news: europe, breaking news: markets, earnings,
Source: https://www.cnbc.com/2024/05/02/novo-nordisk-earnings-q1-2024-weogovy-sales-double.html